Chord Therapeutics
Chord Therapeutics is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, founded in 2014 to develop therapeutics for rare diseases, financed by a 2020 Series A from Omega Funds and operating with a small R&D team.
- Company typePrivate
- Founded2014
- HeadquartersGeneva, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Chord Therapeutics does
Chord Therapeutics is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Geneva, Switzerland. The company focuses on developing therapeutics for rare diseases, operating with a lean team of 1–10 employees consistent with an early-stage clinical development organization. Its business model is typical of venture-backed orphan disease biotechs: the company raises private capital to fund preclinical and clinical development of drug candidates targeting small patient populations, with the intention of either out-licensing assets to larger commercial-stage pharmaceutical companies or advancing programs toward regulatory approval and commercialization. Chord's capital history includes an early-stage round from Eclosion SA in 2015 and a $16 million Series A financing led by Omega Funds in October 2020. Tom Plitz serves as Chief Executive Officer. The company has no disclosed commercial products, partnerships, or revenue-generating arrangements.
A material signal of operational distress is the listing of Chord's primary corporate domain (chordtherapeutics.com) for sale on HugeDomains, a third-party marketplace. Domain disposal at the corporate level is typically inconsistent with active clinical operations, fundraising readiness, or ongoing stakeholder communications, and may indicate wind-down, dissolution, asset sale, or a pivot to an alternative corporate identity. Investors and counterparties should treat this signal as a red flag warranting direct confirmation of the company's current operational status, pipeline status, and corporate continuity before any commercial engagement.
Chord Therapeutics firmographics
Firmographics- Name
- Chord Therapeutics
- Website
- https://chordtherapeutics.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Chord Therapeutics is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, founded in 2014 to develop therapeutics for rare diseases, financed by a 2020 Series A from Omega Funds and operating with a small R&D team.
- Ownership category
- akta.pro rank
Chord Therapeutics industry classification
Industry- Product category
- Rare Disease Therapeutics
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Chord Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Geneva
- HQ country
- Switzerland
- HQ region
- Europe
Markets served
Chord Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Chord Therapeutics product offering
Product offeringCore offering
Chord Therapeutics is a clinical-stage biopharmaceutical company developing drugs for rare diseases. The company is advancing therapeutic candidates through clinical development, with operations headquartered in Geneva, Switzerland, and was founded in 2014. As a clinical-stage company, Chord Therapeutics focuses on identifying and developing pharmaceutical treatments intended for patients with rare disease indications.
Differentiator
Problem solved
Functional benefit
Companies that use Chord Therapeutics
Customer profileIdeal customer profiles1 record
Chord Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Chord Therapeutics partnerships and signals
Strategic signalRecent moves4 records
Chord Therapeutics competitors and assessment
Company assessmentDirect peers
- Catalyst Pharmaceuticals: Catalyst is a clinical-to-commercial specialty pharma focused on rare neurological diseases (e.g., Lambert-Eaton myasthenic syndrome). It is comparable as a small-cap, neurology-focused rare-disease drug developer with overlapping patient populations and similar regulatory/commercial dynamics.
- Sage Therapeutics: Sage develops CNS therapies for rare neurological and neuropsychiatric conditions including status epilepticus and postpartum depression. It is comparable as a clinical-stage rare CNS therapeutics company targeting small orphan-eligible indications.
- BioMarin Pharmaceutical: BioMarin is a rare-disease biopharma with multiple approved therapies for ultra-rare neurological and metabolic conditions. It is comparable as a neurology-and-rare-disease focused drug developer, though at a later commercial stage than Chord.
- Ultragenyx Pharmaceutical: Ultragenyx develops and commercializes therapies for rare and ultra-rare diseases, with several programs in neurological and metabolic disorders. It is comparable as a rare-disease biopharma targeting orphan-eligible neurological indications.
Broad incumbents
- Alexion Pharmaceuticals (AstraZeneca Rare Disease): Alexion, now part of AstraZeneca, is a global rare-disease leader with neurology-adjacent franchises (e.g., NMOSD, gMG). It is comparable as a dominant incumbent in rare neurological therapeutics and a likely strategic acquirer of late-stage CNS assets.
- UCB (Union Chimique Belge): UCB is a Belgium-based biopharma with a strong neurology franchise (e.g., epilepsy, myasthenia gravis). It is comparable as a larger neurology-focused incumbent with overlapping rare neurological indications and a likely strategic acquirer.
Emerging players
- Ionis Pharmaceuticals: Ionis develops antisense oligonucleotide therapies for serious neurological and rare diseases including ALS and Huntington's. It is comparable as a developer of innovative rare CNS therapeutics with overlapping modality/indication ambitions.
- Cycle Pharmaceuticals: Cycle focuses on reformulating existing drugs for rare diseases including neurological conditions. It is comparable as a small specialty pharma pursuing niche rare-disease opportunities through drug repurposing and reformulation.
Regional players
- Centogene: Centogene is a Germany-based rare-disease company combining diagnostics with therapeutics development. It is comparable as a European-headquartered rare-disease player with overlapping CNS/genetic-disease focus and similar regulatory geography.
Others
- Eclosion SA: Eclosion is a Geneva-based biotech creator and seed investor that incubated Chord Therapeutics in 2015. It is comparable as a related ecosystem participant providing insight into Chord's early-stage backing and local biotech network.
Market position
Strengths4 records
Competitive moat2 records
Key risks1 record
Key highlights5 records
Customer concentration
Chord Therapeutics social profiles
Digital presenceChord Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Chord Therapeutics leadership team
Management profileNumber of profiles
Profiles1 record
Chord Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Chord Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Chord Therapeutics
What does Chord Therapeutics do?
Chord Therapeutics is a clinical-stage biopharmaceutical company developing drugs for rare diseases. The company is advancing therapeutic candidates through clinical development, with operations headquartered in Geneva, Switzerland, and was founded in 2014. As a clinical-stage company, Chord Therapeutics focuses on identifying and developing pharmaceutical treatments intended for patients with rare disease indications.
When was Chord Therapeutics founded?
Chord Therapeutics was founded in 2014. It employs 1 to 10 people.
Where is Chord Therapeutics based?
Chord Therapeutics is headquartered in Geneva, Switzerland, in the Europe region.
Who are Chord Therapeutics's main competitors?
Direct peers on record are Catalyst Pharmaceuticals, Sage Therapeutics, BioMarin Pharmaceutical and Ultragenyx Pharmaceutical. Broad incumbents are Alexion Pharmaceuticals (AstraZeneca Rare Disease) and UCB (Union Chimique Belge). Emerging players are Ionis Pharmaceuticals and Cycle Pharmaceuticals. Centogene is listed as a regional player. Eclosion SA is listed as an others.
Does Chord Therapeutics have an API?
No public API is recorded for Chord Therapeutics.
What industry is Chord Therapeutics in?
Chord Therapeutics's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.